190 related articles for article (PubMed ID: 1819738)
1. Differential effect of a PAF antagonist CV-3988 on active and passive anaphylactic shock in various mouse strains.
Arimura A; Harada M
Lipids; 1991 Dec; 26(12):1386-90. PubMed ID: 1819738
[TBL] [Abstract][Full Text] [Related]
2. Suppressive effects of antihistaminic and/or anti-PAF agents on passive anaphylactic shock in mice sensitized with allogeneic monoclonal IgE and IgG1 antibodies and hyperimmune serum.
Kimura S; Watanabe A; Takeuchi M; Nagata M; Harada M
Immunol Invest; 1998 Dec; 27(6):379-93. PubMed ID: 9845423
[TBL] [Abstract][Full Text] [Related]
3. Heterogeneity of drug susceptibility of mouse active anaphylactic shock.
Kimura S; Watanabe A; Nagata M; Niinomi Y; Harada M
Immunol Invest; 1996; 25(5-6):425-34. PubMed ID: 8915680
[TBL] [Abstract][Full Text] [Related]
4. High susceptibility of cataract Shionogi (CTS) mice to passive anaphylactic shock mediated by allogeneic IgE and IgG1 monoclonal antibodies.
Harada M; Nagata M; Takeuchi M; Makino S; Aburahi S
Immunol Invest; 1991 Jun; 20(3):305-15. PubMed ID: 1874560
[TBL] [Abstract][Full Text] [Related]
5. Production of active and passive anaphylactic shock in the WBB6F1 mouse, a mast cell-deficient strain.
Arimura A; Nagata M; Watanabe A; Nakamura K; Takeuchi M; Harada M
Experientia; 1990 Jul; 46(7):739-42. PubMed ID: 2373200
[TBL] [Abstract][Full Text] [Related]
6. Age-dependent difference in susceptibility to IgE antibody- and IgG1 antibody-mediated passive anaphylactic shock in the mouse.
Harada M; Nagata M; Takeuchi M; Ohara T; Makino S; Watanabe A
Immunol Invest; 1991; 20(5-6):515-23. PubMed ID: 1791039
[TBL] [Abstract][Full Text] [Related]
7. Beneficial effects of TCV-309, a novel potent and selective platelet activating factor antagonist in endotoxin and anaphylactic shock in rodents.
Terashita Z; Kawamura M; Takatani M; Tsushima S; Imura Y; Nishikawa K
J Pharmacol Exp Ther; 1992 Feb; 260(2):748-55. PubMed ID: 1738121
[TBL] [Abstract][Full Text] [Related]
8. A lethal role of platelet activating factor in anaphylactic shock in mice.
Terashita Z; Imura Y; Shino A; Nishikawa K
J Pharmacol Exp Ther; 1987 Oct; 243(1):378-83. PubMed ID: 3118009
[TBL] [Abstract][Full Text] [Related]
9. Effect of CV-3988, a specific antagonist against platelet activating factor, on homologous passive cutaneous anaphylaxis in the mouse ear.
Inagaki N; Miura T; Ohira K; Nagai H; Xu QA; Koda A
J Pharmacobiodyn; 1990 May; 13(5):272-7. PubMed ID: 2177106
[TBL] [Abstract][Full Text] [Related]
10. A biotinylated peptide, BP21, as a novel potent anti-anaphylactic agent targeting platelet-activating factor.
Sato A; Ebina K
J Pept Sci; 2017 Sep; 23(9):727-735. PubMed ID: 28627122
[TBL] [Abstract][Full Text] [Related]
11. Effect of the hetrazepinoic platelet-activating factor antagonist Bepafant (WEB 2170) in models of active and passive anaphylaxis in mice and guinea pigs.
Heuer HO
Lipids; 1991 Dec; 26(12):1374-80. PubMed ID: 1819736
[TBL] [Abstract][Full Text] [Related]
12. Effect of the PAF antagonists, CV-3988 and L-652,731 on the pulmonary and hematological responses to guinea pig anaphylaxis.
Danko G; Sherwood JE; Grissom B; Kreutner W; Chapman RW
Pharmacol Res Commun; 1988 Sep; 20(9):785-98. PubMed ID: 3174804
[TBL] [Abstract][Full Text] [Related]
13. Effects of a platelet-activating factor antagonist, CV-3988, on different shock models in the rat.
Toth PD; Mikulaschek AW
Circ Shock; 1986; 20(3):193-203. PubMed ID: 3802423
[TBL] [Abstract][Full Text] [Related]
14. Interference by the novel PAF-acether antagonist WEB 2086 with the bronchopulmonary responses to PAF-acether and to active and passive anaphylactic shock in guinea-pigs.
Pretolani M; Lefort J; Malanchère E; Vargaftig BB
Eur J Pharmacol; 1987 Aug; 140(3):311-21. PubMed ID: 3653247
[TBL] [Abstract][Full Text] [Related]
15. Immune deficiency of cataract Shionogi (CTS) mouse. II. Impaired in vivo T cell-mediated immune response.
Yagi H; Nagata M; Takeuchi M; Watanabe A; Arimura A; Hashimoto S; Makino S; Harada M
Immunol Invest; 1990; 19(5-6):493-505. PubMed ID: 2074115
[TBL] [Abstract][Full Text] [Related]
16. Mouse anaphylactic shock is caused by reduced cardiac output, but not by systemic vasodilatation or pulmonary vasoconstriction, via PAF and histamine.
Wang M; Shibamoto T; Tanida M; Kuda Y; Kurata Y
Life Sci; 2014 Oct; 116(2):98-105. PubMed ID: 25252221
[TBL] [Abstract][Full Text] [Related]
17. PAF, rather than histamine, participates in mouse anaphylactic hypotension.
Shibamoto T; Liu W; Cui S; Zhang W; Takano H; Kurata Y
Pharmacology; 2008; 82(2):114-20. PubMed ID: 18583921
[TBL] [Abstract][Full Text] [Related]
18. Platelet-activating factor in the inflammatory exudate in the anaphylactic phase of allergic inflammation in rats.
Watanabe M; Ohuchi K; Sugidachi A; Hirasawa N; Hayashi Y; Tsurufuji S
Int Arch Allergy Appl Immunol; 1987; 84(4):396-403. PubMed ID: 3119503
[TBL] [Abstract][Full Text] [Related]
19. Inhibitory effects of the novel platelet activating factor receptor antagonist, 1-ethyl-2-[N-(2-methoxy)benzoyl-N-[(2R)-2-methoxy-3-(4- octadecylcarbamoyloxy) piperidinocarbonyloxypropyloxy]carbonyl] aminomethyl-pyridinium chloride, in several experimentally induced shock models.
Nagaoka J; Harada K; Kimura A; Kobayashi S; Murakami M; Yoshimura T; Yamada K; Asano O; Katayama K; Yamatsu I
Arzneimittelforschung; 1991 Jul; 41(7):719-24. PubMed ID: 1663352
[TBL] [Abstract][Full Text] [Related]
20. Protective effect of SR 27417, a novel PAF antagonist, on lethal anaphylactic and endotoxin-induced shock in mice.
Herbert JM; Lespy L; Maffrand JP
Eur J Pharmacol; 1991 Dec; 205(3):271-6. PubMed ID: 1817964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
